Quantitative proteomics profiling reveals activation of mTOR pathway in trastuzumab resistance

Trastuzumab is an antibody-based therapy drug targeting HER2-overexpressing tumors. While it has been proven to be very successful initially, most patients eventually develop resistance to trastuzumab. The mechanism of drug resistance is not well understood. Identifying pathways that mediate trastuz...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Liu, Wenhu, Chang, Jinxia, Liu, Mingwei, Yuan, Jiangbei, Zhang, Jinqiang, Qin, Jun, Xia, Xuefeng, Wang, Yi
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2017
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5542228/
https://ncbi.nlm.nih.gov/pubmed/28507275
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17415
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires